Whole genome analysis of the action of interferon-beta

Int J Clin Pharmacol Ther. 2009 May;47(5):328-57. doi: 10.5414/cpp47328.


Objectives: To characterize the IFNbeta1a-regulated gene expression on leukocytes of Multiple Sclerosis (MS) patients using microarrays with whole human genome representation.

Methods: Genes differentially expressed by interferon-beta were identified by a microarray in vitro study performed in leukocytes obtained from 5 MS relapsing-remitting patients.

Results: Following the culture of peripheral blood mononuclear cells from MS relapsing-remitting patients for 24 hs with IFNbeta1a, the expression of 868 genes was modified: 545 increased (including CXCL11, CCL8, INDO, IFI27, CFB, CXCL10 and IFIT1) and 323 diminished (including RBP7, SEPT5, RNF8, ADORA2B and FOS).

Conclusions: Since many of them were previously recognized as involved in MS pathogenesis, the IFNbeta1a mechanism of action could imply a compensatory regulation of systems deregulated in MS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / pharmacology*
  • Adolescent
  • Adult
  • Female
  • Gene Expression Profiling / methods
  • Gene Expression Regulation / drug effects*
  • Genome, Human
  • Humans
  • In Vitro Techniques
  • Interferon beta-1a
  • Interferon-beta / pharmacology*
  • Leukocytes, Mononuclear / drug effects
  • Male
  • Middle Aged
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / genetics
  • Oligonucleotide Array Sequence Analysis / methods
  • Reverse Transcriptase Polymerase Chain Reaction
  • Young Adult


  • Adjuvants, Immunologic
  • Interferon-beta
  • Interferon beta-1a